



4 March 2021

Appointment of Bruce Robinson AC to the Ecofibre Board

Ecofibre Limited (Ecofibre, Company) (ASX:EOF, US ADR: EOFBY) announces the appointment of Professor Bruce Robinson AC as a director of the Company effective 4 March 2021.

Prof. Robinson has over 25 years leadership experience as a board director, academic physician and scientist across research, healthcare and medicine, and tertiary education. He has extensive experience covering academia, government, public and private health providers, research institutes and philanthropic organisations.

He is currently a director of Cochlear, an ASX listed global hearing implants business; MaynePharma, an ASX listed pharmaceutical manufacturer; and QBiotics, a drug development company.

Since 2015 Prof. Robinson has also chaired the Australian Government's National Health and Medical Research Council, and the Medical Benefits Schedule Review Task Force.

His prior professional experience includes Dean of University of Sydney's Sydney Medical School, Head of Medicine at Sydney's Royal North Shore Hospital and Head of the Cancer Genetics Laboratory at the Kolling Institute for Medical Research.

Ecofibre Chairman, Mr Barry Lambert welcomed Prof. Robinson to the Board, and said that his appointment aligned with Ecofibre's focus on health and patient outcomes.

"Bruce's deep medical experience and leadership across research, academia, health administration and government as well as public and private health providers makes him an important addition to the Board."

"In 2020, Bruce was one of only five people to be appointed Companion of the Order of Australia, the highest honour, for eminent achievement and merit of the highest degree in service to Australia or to humanity at large. He received his award for service to medical research, and to national healthcare, through policy development and reform, and to tertiary education."





In announcing the appointment, Mr Lambert said he has known Prof. Robinson through their mutual involvement with Sydney University's Lambert Initiative for Cannabinoid Therapeutics, as well as the growing international medical company Q-Biotics.

"Bruce is not only a world-class medical professional, but he also possesses valuable commercial and public company experience as a director of major Australian healthcare businesses."

Prof. Robinson said, 'I have been impressed with Ecofibre's strategic investment in clinical research, which includes a range of studies across multiple conditions. I look forward to working with management to help commercialise the benefits of this important investment in due course.'

Prof. Robinson's appointment takes the number of Directors on the Ecofibre Board to five. He will be a non-executive Director and is considered by the Board to be independent.

As noted by the Company at the 2020 Annual General Meeting, a further significant Director appointment is expected to be announced prior to Mr Lambert's retirement from the Board later this year.

Summary of Experience

2015 - present	Chair of the National Health and Medical Research Council
2015 - present	Chair of the Medical Benefits Schedule Review Taskforce
2007 - 2016	Dean, Sydney Medical School
1998 - 2006	Head, Division of Medicine, Royal North Shore Hospital
1990 - 2008	Head, Cancer Genetics Laboratory, Kolling Institute for Medical Research
Boards	Cochlear, 2015 - present
	QBiotics, 2015 - present
	MaynePharma, 2014 - present
	Woolcock Institute, 2006 - present
Qualifications	MD, MSc, FRACP, FAAHMS, FAICD





Investor Relations and Media please contact:

Jonathan Brown, Company Secretary, Ecofibre Limited
Level 12, 680 George Street, Sydney NSW 2000
investor-relations@ecofibre.com

About Ecofibre

Ecofibre is a provider of hemp products in the United States and Australia.

In the United States, the Company produces nutraceutical products for human and pet consumption, as well as topical creams and salves. See www.anandahemp.com and www.anandaprofessional.com.

In Australia, the Company grows and produces hemp food products including protein powders, de-hulled hemp seed and hemp oil. See www.anandafood.com.

The Company also develops and produces innovative hemp-based textile products in the United States. See www.hempblack.com.

The Company owns or controls key parts of the value chain in each business, from breeding, growing and production to sales and marketing. Our value proposition to customers is built on strong brands and quality products.

Authorisation

This document is authorised to be given to the Australian Securities Exchange (ASX) by the Board of the Company.

